New Day Diagnostics is set to acquire assets and intellectual property from Epigenomics AG, a molecular diagnostics company specializing in early cancer detection through blood testing. This move will enhance New Day Diagnostics’ cancer diagnostics offerings and incorporate Epigenomics’ biomarker technology for detecting methylated DNA in cancer, including Epi proColon, a colorectal cancer screening tool.
What You Should Know:
- New Day Diagnostics LLC announced it has entered into an agreement to acquire the assets of Epigenomics AG, a molecular diagnostics company focused on blood testing for the early detection of cancer.
- Under the terms of the agreement, New Day Diagnostics would acquire substantially all of Epigenomics AG’s assets and intellectual property.
- The acquisition would expand New Day Diagnostics’ portfolio in the cancer diagnostics space and include proprietary biomarker technology for the detection of methylated DNA in various cancer indications, including Epi proColon, a screening tool for the non-invasive detection of colorectal cancer.
Source: HitConsultant
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
